PMID- 32641127 OWN - NLM STAT- MEDLINE DCOM- 20201026 LR - 20201026 IS - 1475-2840 (Electronic) IS - 1475-2840 (Linking) VI - 19 IP - 1 DP - 2020 Jul 8 TI - Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China. PG - 108 LID - 10.1186/s12933-020-01086-5 [doi] LID - 108 AB - BACKGROUND: The relationship between triglyceride-glucose index (TyG index) and the prevalence and prognosis of cardiovascular disease has been confirmed by former studies. However, it remains uncertain whether TyG index has a prognostic impact in patients with type 2 diabetes mellitus (T2DM) and non-ST-segment elevation acute coronary syndrome (NSTE-ACS) undergoing percutaneous coronary intervention (PCI). METHODS: The study retrospectively enrolled 798 patients (mean age: 60.9 +/- 8.3 years; 68.3% men) with T2DM and NSTE-ACS who underwent PCI at Beijing Anzhen Hospital from January to December 2015. TyG index was calculated as previously reported: ln [fasting TGs (mg/dL) * FBG (mg/dL)/2]. The primary endpoint was a composite of adverse events as follows: all-cause death, non-fatal myocardial infarction (MI) and ischemia-driven revascularization. RESULTS: TyG index was significantly higher in patients with a primary endpoint event compared with those without. Multivariate Cox proportional hazards analysis showed that 1-unit increase of TyG index was independently associated with higher risk of primary endpoint, independent of other risk factors [hazard ratio (HR) 3.208 per 1-unit increase, 95% confidence interval (CI) 2.400-4.289, P < 0.001]. The addition of TyG index to a baseline risk model had an incremental effect on the predictive value for adverse prognosis [AUC: baseline risk model, 0.800 vs. baseline risk model + TyG index, 0.856, P for comparison < 0.001; category-free net reclassification improvement (NRI) 0.346, P < 0.001; integrated discrimination improvement (IDI) 0.087, P < 0.001]. CONCLUSIONS: Increased TyG index is a significant predictor of adverse prognosis in patients with T2DM and NSTE-ACS undergoing PCI. Further studies need to be performed to determine whether interventions for TyG index have a positive impact on improving clinical prognosis. FAU - Zhao, Qi AU - Zhao Q AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, 100029, China. FAU - Zhang, Ting-Yu AU - Zhang TY AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, 100029, China. FAU - Cheng, Yu-Jing AU - Cheng YJ AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, 100029, China. FAU - Ma, Yue AU - Ma Y AD - Research Center for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China. FAU - Xu, Ying-Kai AU - Xu YK AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, 100029, China. FAU - Yang, Jia-Qi AU - Yang JQ AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, 100029, China. FAU - Zhou, Yu-Jie AU - Zhou YJ AUID- ORCID: 0000-0002-9545-1984 AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, 100029, China. azzyj12@163.com. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20200708 PL - England TA - Cardiovasc Diabetol JT - Cardiovascular diabetology JID - 101147637 RN - 0 (Biomarkers) RN - 0 (Blood Glucose) RN - 0 (Triglycerides) SB - IM MH - Acute Coronary Syndrome/*blood/diagnosis/mortality/therapy MH - Aged MH - Beijing/epidemiology MH - Biomarkers/blood MH - Blood Glucose/*metabolism MH - Cause of Death MH - Diabetes Mellitus, Type 2/*blood/diagnosis/mortality/therapy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Myocardial Revascularization MH - Non-ST Elevated Myocardial Infarction/*blood/diagnosis/mortality/therapy MH - Prognosis MH - Retrospective Studies MH - Risk Assessment MH - Risk Factors MH - Time Factors MH - Triglycerides/*blood PMC - PMC7341665 OTO - NOTNLM OT - Non-ST-segment elevation acute coronary syndrome OT - Percutaneous coronary intervention OT - Triglyceride-glucose index OT - Type 2 diabetes mellitus COIS- The authors declare that they have no competing interests. EDAT- 2020/07/10 06:00 MHDA- 2020/10/27 06:00 PMCR- 2020/07/08 CRDT- 2020/07/10 06:00 PHST- 2020/05/12 00:00 [received] PHST- 2020/07/02 00:00 [accepted] PHST- 2020/07/10 06:00 [entrez] PHST- 2020/07/10 06:00 [pubmed] PHST- 2020/10/27 06:00 [medline] PHST- 2020/07/08 00:00 [pmc-release] AID - 10.1186/s12933-020-01086-5 [pii] AID - 1086 [pii] AID - 10.1186/s12933-020-01086-5 [doi] PST - epublish SO - Cardiovasc Diabetol. 2020 Jul 8;19(1):108. doi: 10.1186/s12933-020-01086-5.